Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda

AIDS Research and Human Retroviruses

Volumn 26, Issue 5, 2010, Pages 563-568

  Towler, William I ^a   Barlow Mosha, Linda ^b   Church, Jessica D ^a   Bagenda, Danstan ^b,c   Ajuna, Patrick ^b   Mubiru, Micheal ^b   Musoke, Philippa ^b,c   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; POINT MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE DRUG DOSE; TREATMENT RESPONSE; UGANDA;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MOLECULAR SEQUENCE DATA; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; STAVUDINE; TREATMENT OUTCOME; UGANDA;

EID: 77952556299     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0164     Document Type: Article

References (20)

1. The-KIDS-ART-LINC-Collaboration: Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in sub-Saharan Africa. J Acquir Immune Defic Syndr 2008;49:523-531.
2. Sutcliffe CG, van Dijk JH, Bolton C, et al.: Effectiveness of antiretroviral therapy among HIV-infected children in sub- Saharan Africa. Lancet Infect Dis 2008;8:477-489.
3. Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
4. McConnell MS, Stringer JS, Kourtis AP, et al.: Use of singledose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstet Gynecol 2007;197:S56-S63.
5. Martinson NA, Morris L, Gray G, et al.: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
6. Church JD, Mwatha A, Bagenda D, et al.: In utero HIV infection is associated with an increased risk of nevirapine resistance in Ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses 2009;25:673-677.
7. Lockman S. Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. Curr Opin HIV AIDS 2008;3:166-172.
8. Eshleman SH, Krogstad P, Jackson JB, et al.: Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 2001;183: 1732-1738.
9. Barlow-Mosha L, Ajunua P, Mubiru M, et al.: Early effectiveness of a NVP-based HAART regimen among HIVinfected children with and without prior single-dose NVP exposure. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2008.
10. Musoke PM, Barlow-Mosha L, Bagenda D, et al.: Response to highly active antiretroviral therapy in HIV infected Ugandan children exposed and not exposed to single dose nevirapine at birth. J AIDS 2009;52:560-568.
11. McConnell M, Bakaki P, Eure C, et al.: Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. J Acquir Immune Defic Syndr 2007;46:291-296.
12. Eshleman SH, Guay LA, Mwatha A, et al.: Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-130. (Pubitemid 38133734)
13. Church JD, Omer SB, Guay LA, et al.: Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008;198:1075-1082.
14. R-Development-Core-Team. A language and environment for statistical computing. 2007, http://www.R-project.org:ISBN 3-900051-900007-900050.
15. Chaix ML, Rouet F, Kouakoussui KA, et al.: Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J 2005;24:1072-1076.
16. Lwembe R, Ochieng W, Panikulam A, et al.: Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007;79:865-872.
17. Gody JC, Charpentier C, Mbitikon O, et al.: High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations (Letter). J Acquir Immune Defic Syndr 2008;49:566-570.
18. Adje-Toure C, Hanson DL, Talla-Nzussouo N, et al.: Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2008;24:911-917.
19. Flys T, Nissley DV, Claasen CW, et al.: Sensitive drugresistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005;192: 24-29.
20. Church JD, Towler WI, Hoover DR, et al.: Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants. AIDS Res Human Retroviruses 2008;24:595-605.